Delivery Order SPE2DR25D2002-SPE2DR26FBSW3
Award Date 12/23/25
Potential Completion Date 12/24/25
Potential Value $61K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $2,447.64 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with completion scheduled for December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, meaning it was competitively awarded. The contract will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for adults 18 years and older, and...
- The Defense Logistics Agency awarded a $139,894.18 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with completion scheduled for July 23, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The work will be performed at...
- The Defense Logistics Agency (DLA) awarded a $37,755.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 8, 2025, with completion due by December 9, 2025. HEPLISAV-B is a recombinant hepatitis B vaccine, and this delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation....
- The Defense Logistics Agency awarded a $53,766.20 delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of HEPLISAV-B 20 mcg/0.5 ml syringes. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 1, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $8,158.80. This is a firm fixed price, non-set-aside contract with an ultimate completion date of December 2, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine, reflecting the Defense Logistics Agency's ongoing pharmaceutical procurement...
- The Defense Logistics Agency awarded a delivery order valued at $8,158.80 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 1, 2025, with an ultimate completion date of December 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded to the prime contractor's corporate office located in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine used for adult immunization, representing part of the...
- The Defense Logistics Agency awarded a delivery order valued at $40,921.90 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 mL syringes on November 7, 2025, with completion targeted for November 10, 2025. This firm fixed-price delivery order, placed without set-aside designation, represents a competitive award under the company's larger pharmaceutical supply vehicle with DLA. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a delivery order valued at $1,955.95 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 12, 2025, with an ultimate completion date of December 15, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for prevention of hepatitis B...
- The Defense Logistics Agency awarded a delivery order valued at $6,819.50 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on December 4, 2025, with completion targeted for December 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's facility in...